

11-15-00

A

11/13/00
jc945 U.S. PTO

jc914 U.S. PTO
09/11/2028
11/13/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Docket No. A-65182-1/RFT/JJD

Anticipated Classification of
this Application:

Class: Subclass:

Prior Application:

Examiner: Moezie, F.

Art Unit: 1654

"EXPRESS MAIL" MAILING LABEL

NUMBER EL659498644US

DATE OF DEPOSIT November 13, 2000

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
"EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 3
CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED
TO: BOX PATENT APPLICATION FEE, ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, DC 20231.

TYPED NAME Vincent Diaz

SIGNED

Box PATENT APPLICATION

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

This is a request for filing an

___ Original

___ Continuation

___ Divisional

X Continuation-in-part

application under 37 C.F.R. 1.53(b), in the names of (1) **Paul H. PATTERSON, Altadena, California;** and
(2) **Clifford J. WOOLF, Newton, Massachusetts** for **LIF FOR USE IN MODULATING INFLAMMATION
AND PAIN**. This continuation-in-part application claims priority to pending application Serial No. **09/173,433**
filed on **October 15, 1998**.

1. (a) ___ Enclosed is a new application.
- (b) X Enclosed is a continuation-in-part application.
- (c) ___ Enclosed is a copy of the prior application.

2. (a) ☐ Enclosed is a new Declaration.
 (b) ☐ Enclosed is a copy of the prior executed Declaration as originally filed.
 (c) ☐ Enclosed is a Combined Declaration/Power of Attorney.

3. (a) ☐ Enclosed is a Small Entity Affidavit.
 (b) ☒ A Small Entity Affidavit is of record in the prior application.

4. ☒ The filing fee is calculated below:

Claims as filed in the prior application, less any claims canceled by amendment below:

	(Col. 1) NO. FILED	(Col. 2) NO. EXTRA	SMALL ENTITY RATE FEE	OTHER THAN SMALL ENTITY RATE FEE
BASIC FEE			\$355	\$710
TOTAL CLAIMS	27 - 20 = 7	7	x 9 = \$ 63	x 18 = \$
INDEP CLAIMS	4 - 3 = 0	1	x 40 = \$ 40	x 80 = \$
MULTIPLE DEPENDENT CLAIM PRESENTED			+ 135 = \$135	+ 270 = \$
If the difference in Col 1 is less than zero, enter "0" in Col. 2			TOTAL	TOTAL
			\$593	\$

5. ☐ The Commissioner is hereby authorized to charge any additional fees which may be required, including extension fees, or credit any overpayment to Deposit Account No. 06-1300 (Order No. A-67727-1/RFT)

6. ☐ Our check in the amount of \$_____ is enclosed.

7. ☐ Cancel in this application original claims _____ of the prior application before calculating the filing fee. (At least one independent claim must be retained for filing purposes.)

8. ☐ Amend the specification by inserting before the first line the sentence:

--This is a continuation-in-part application of application Serial No. 09/173,433 filed on October 15, 1998, which is a continuing application of U.S. provisional application Serial No. 60/062,049, filed October 15, 1997. --

9. (a) ☒ Informal drawings are enclosed, 12 sheets.
 (b) ☐ Formal drawings are enclosed, _____ sheets.

10.(a) ____ Priority of application Serial No. ____ filed on ____ in ____ is claimed under 35 U.S.C. 119.

(b) ____ The certified copy has been filed in prior application Serial No. ____ filed on ____.

11. ____ An Assignment is enclosed.

12. ____ The prior application is assigned of record to California Institute of Technology

13. ____ A Power of Attorney by Assignee is enclosed.

14. X The power of attorney in the prior application is to:

FLEHR HOHBACH TEST ALBRITTON & HERBERT LLP
Suite 3400, Four Embarcadero Center
San Francisco, California 94111-4187

(a) X The power appears in the original papers in the prior application.

(b) ____ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.

(c) X Address all future communications to:

Richard F. Trecartin, Esq.
FLEHR HOHBACH TEST ALBRITTON & HERBERT LLP
Suite 3400, Four Embarcadero Center
San Francisco, California 94111-4187
Telephone: (415) 781-1989

15. ____ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)


16. ____ A Prior Art Statement is enclosed.

17. X I hereby verify that the attached papers, where indicated, are a true duplicate of prior application Serial No. 09/173,433 as originally filed on October 15, 1998.

Date: November 13, 2000

Address of Signer:

FLEHR HOHBACH TEST
ALBRITTON & HERBERT LLP
Four Embarcadero Center, Suite 3400
San Francisco, California 94111


Richard F. Trecartin, Reg. No. 31,801

X Attorney or agent of record

____ Filed under Section 1.34(a)

LIF FOR USE IN MODULATING INFLAMMATION AND PAIN

Field of the Invention

This invention is related to the use of leukemia inhibitory factor (LIF) and other agonists of the LIF receptor, in the regulation of inflammation and pain.

Sponsorship

The U.S. Government has certain rights in this invention pursuant to Grant No. NS 20916 awarded by the National Institute of Health.

Background

Leukemia inhibitory factor (LIF) belongs to the neuropoietic cytokine family, which also includes ciliary neurotrophic factor (CNTF), oncostatin M (OSM), growth promoting activity, cardiotrophin-1, and interleukin-6 and -11 (IL-6 and IL-11). All of these cytokines are pluripotent, having effects on proliferation and gene expression in a wide variety of cell types in culture. Moreover, all of these cytokines can utilize the same signal transducing receptor subunit, gp130, which exists in a number of different cell types.

LIF has been implicated as having a role in both the neural and immune responses to injury (Patterson PH (1994) *Proc Natl Acad Sci USA* 91:7833-7835). For example, within the nervous system, LIF mRNA levels dramatically increase soon

after injury (Patterson PH (1994) *Proc Natl Acad Sci USA* 91:7833-7835; Kurek JB, et al, (1996) *Neuromusc Disorders* 6:105-114; Banner, LR, et al, (1997) *Exper Neurol*, in press), and experiments with LIF null mutant (knockout) mice demonstrate that LIF is required for the changes in neuronal gene expression that are characteristic of the injury response (Rao MS, et al, (1993) *Neuron* 11:1175-1185; Corness J, et al, (1996) *Exp Brain Res* 112:79-88; and Sun Y, Zigmond RE (1996) *Eur J Neurosci* 8:2213-2220). Following sciatic nerve injury, LIF is required for normal inflammatory cell infiltration, and LIF is directly and indirectly chemotactic for macrophages (Sugiura S, et al., (2000) *Eur. J. Neurosci.* 12: 457-466; Tofaris GK, et al., (2000) *Soc. Neurosci. Abstr., in press*). Lack of LIF can also lead to premature neuronal death (Sendtner M, et al, (1996) *Curr Biol* 6:686-694). Moreover, addition of LIF to severed nerves can enhance nerve regeneration and functional recovery (Tham S, et al, (1997) *J Neurosci Res* 47:208-215).

Studies have also reported that LIF levels are increased in a variety of animal and human inflammatory conditions (Alexander HR, et al, (1994) *Cytokine* 6:589-596; Brown et al, (1994) *Cytokine* 6:300-309; Ulich TR, et al, (1994) *Amer Physiol Soc* 267:442-446; and Heyman D, et al, (1996) *Cytokine* 8:410-416). Inflammation of the skin is a serious medical problem. Depending on the country, epidermal irritants and allergic reactions comprise 20-70% of all occupational diseases. There are also chronic skin diseases such as psoriasis, which is one of the most common immune-mediated diseases in humans, affecting 2-3% of the population. In addition, excessive exposure to ultraviolet radiation can cause inflammation as well as local and systemic immunosuppression and skin cancer. In each of these conditions, cytokines play a key role in initiating and maintaining pathophysiology as well as in inducing recovery (Ullrich S.E. (1995) *Photochem. Photobiol.* 62: 389-401; Asadullah K, et al., (1999) *Drugs of Today* 35: 913-924; Bonifati C, et al., (1999) *Int. J. Dermat.* 38: 241-251; Corsini E, et al., (2000) *Toxicology* 142: 203-211). Of these cytokines, tumor necrosis factor (TNF) and IL-1 are considered to be primary initiators of cutaneous inflammation, with IL-4, -6, -7, -8, -10, -11, IFN- γ and transforming growth factor (TGF) β also being implicated. For example, in the chronic cutaneous inflammatory

condition of psoriasis, a number of type 1 cytokines are up-regulated, including IL-2, IL-6, IL-8, IL-12, IL-18, IFN- γ and TNF α , while relatively low levels of anti-inflammatory cytokines such as IL-1RA and IL-10 have been found (Ullrich S.E. (1995) *Photochem. Photobiol.* 62: 389-401; Asadullah K, et al., (1999) *Drugs of Today* 35: 913-924; Bonifati C, et al., (1999) *Int. J. Dermat.* 38: 241-251; Corsini E, et al., (2000) *Toxicology* 142: 203-211; Naik SM, et al., (1999) *J. Invest. Dermatol.* 113: 766-772). The cytokines that play key regulatory roles in this signaling cascade are of clinical interest as potential targets of therapeutic intervention; e.g., subcutaneous delivery of IL-10 or -11 to patients with psoriasis can ameliorate this condition (Asaduliah K, et al., (1998) *J. Clin. Invest.* 101: 783-794; Trepicchio WL, et al., (1999) *J. Clin. Invest.* 104: 1527-1537).

Leukemia inhibitory factor is also of interest in this context, as this cytokine can induce pro-inflammatory as well as anti-inflammatory effects, depending on the tissue and the form of perturbation (reviewed in Gadiant R, et al., (1999) *Stem Cells* 17: 127-137). In the periphery, injection of high concentrations of LIF into skin or joints can induce swelling and leukocyte invasion (Carroll GJ, et al., (1995) *J. Interferon. Cytokine Res.* 15: 567-573; McKenzie RC, et al., (1996) *Acta Derm. Venereol. (Stockh)* 76: 111-114). Injection of high doses of LIF into the ear pinnae of mice increased ear thickness (McKenzie RC, et al., (1996) *Acta Derm. Venereol. (Stockh)* 76: 111-114), and systemic injection of high levels of LIF induced a prolonged hypersensitivity to mechanical stimulation (Thompson SWN, et al., (1996) *Neuroscience* 71: 1091-1094).

While these studies implicate LIF as having a role in the nervous and immune systems, there is a need to establish the interactions between the nervous and immune systems during the injury response. Accordingly, it is an object herein to determine the role of LIF in response to or in anticipation of injury, trauma or disorders associated with inflammation and/or pain, and to use LIF to modulate inflammation and pain, individually or together.

It is further an object to use biologically active fragments of LIF and other agonists of the LIF receptor to modulate inflammation and/or pain. It is further an object to administer or upregulate LIF or other agonists of the LIF receptor and particularly the signal transducing receptor subunit gp130, in an individual prior to or simultaneous with activities such as sports, hard labor, or undertaking surgery which generally result in inflammation and pain. It is additionally an object to provide a method of using LIF to prevent and/or reduce the inflammation and/or pain associated with Rheumatoid arthritis.

It is also an object herein to provide methods for screening for modulators of LIF and/or LIF activity, particularly those which enhance the anti-inflammatory activity of LIF.

Summary of the Invention

In accordance with the objectives of the application set forth herein, a method for inhibiting and/or reducing inflammation in an individual is provided. The method comprises administration of leukemia inhibitory factor (LIF) to a cell or an individual in an amount effective to inhibit and/or reduce inflammation.

In one aspect, administration of LIF is prior to an activity or condition which is known to result in inflammation. Alternatively, administration occurs during or preferably, at the onset of the activity or condition.

Administration of LIF in accordance with the present invention is preferably to a site of inflammation or potential inflammation. Administration can be in conjunction with a transdermal formulation, injected or applied topically directly to a site, i.e., an open wound or surgical site. In a preferred embodiment, LIF protein is administered. In another embodiment, nucleic acid encoding LIF is administered, preferably using a viral vector.

The methods provided herein also are directed to the administration of LIF to reduce

and/or inhibit pain. The method comprises the administration of LIF to an individual in an amount effective to inhibit and/or reduce the pain.

Methods are also provided herein wherein candidate agents are screened for their ability to modulate the activity of LIF. The method comprises administering LIF to a cell or animal model in the presence of the candidate agent and determining the activity of LIF.

Brief Description of the Drawings

Figures 1A, 1B and 1C each show a bar graph indicating the results of LIF knockout mice compared to wild type mice. Figure 1A shows the results on IL-1 β , Figure 1B shows the results on nerve growth factor (NGF), and Figure 1C shows the results on swelling. Wild type (WT) is shown as +/+ and LIF null mutants are shown as -/-. Swelling is expressed as the change in the dorsal-ventral paw diameter value from pre-inflamed levels in WT (+/+) and LIF (-/-) null mutant mice. The % increase in the mutant mouse was substantially greater ($p < 0.01$ Mann-Whitney U test) than in the WT. N=12 for naive, WT and 6 for all other groups.

Figures 2A and 2B are a photograph showing the results of hematoxylin and eosin staining of footpad skin. Figure 2A shows results from the LIF knockout mice, and Figure 2B shows results from wildtype. Hematoxylin and eosin staining of the footpad skin, 48 hours after complete Freund's adjuvant (CFA) injection, reveals more polymorphonuclear neutrophils (arrowhead) in the dermis of (-/-) compared to (+/+). Scale bar denotes 20 μ m.

Figures 3A and 3B are graphs showing the results of administration of LIF to the paw after inducing inflammation. Figure 3A shows mechanical sensitivity and Figure 3B shows thermal sensitivity. “***” indicates $p < 0.001$ and “**” indicates $p < 0.01$. N=6 for each data point.

Figures 4A and 4B each show a bar graph of LIF knock out mice versus wild type.

Figure 4A shows the results of NGF and Figure 4B shows the results of IL-1 β . N=4; *p < 0.05 CFA vs. naive; # p < 0.05 CFA + 100 ng LIF vs. CFA.

Figure 5 is a graph showing intraplantar injection of LIF at 50 (diamond), 100 (open circle) and 500 (closed circle) ng into the paws of noninflamed rats. *p < 0.05; **p < 0.01, N = 4 for each data point.

Figures 6A-6D are photographs of adult mouse footpad showing expression of LIF and/or β -galactosidase following infection with AdLIF and AdLacZ. Four days following injection of AdLacZ virus (6A) or control AdPacI virus (6B) sections were stained for β -galactosidase activity. Stained cells are seen only in the case of AdLacZ infection. Sections of footpads taken four days following injected with both AdLIF and AdLacZ (6C) or just AdLacZ (6D) were stained for both LIF and β -galactosidase. Cells stained with the anti-LIF antibody are found in 6C but not in 6D. Moreover, some cells in 6C are double labeled for LIF and β -galactosidase (arrow). These results, taken together with the results of the culture assays (see text), indicate that AdLIF successfully infects the skin and results in the expression of LIF protein and activity. (200x magnification)

Figure 7 shows a bar graph comparing the effect of endogenous and exogenously delivered LIF on edema induced by CFA. Both wild type (WT) and leukemia inhibitory factor knock-out (LIF KO) mouse footpads were injected with CFA and edema was examined 48 hrs later. Swelling is expressed as the per cent change in the dorsoventral paw diameter compared to pre-CFA treatment levels. The open bars display the data from controls that were injected with CFA and AdLacZ. The striped bars display the data from paws injected with CFA and AdLIF. Edema in the KO footpad is significantly greater than in the WT (**p<0.001). In addition, injection of AdLIF significantly reduces the swelling response to CFA in both WT and LIF KO skin. (*p<0.001)

Figures 8A-8H show photographs of representative sections of footpads

immunostained for Mac-1 two days after viral injection (A, C, E, G) or virus and CFA injection (B, D, F, H). Footpads from WT (A-D) and LIF KO (E-H) were injected with either AdLacZ (A, B, E, F) or AdLIF (C, D, G, H). In both genotypes, CFA elicited an increase in Mac-1 staining, and AdLIF reduced this increase. In addition, CFA elicited much greater Mac-1 staining in the LIF KO than in the WT (B vs. D). No increase in staining was seen in AdLacZ infected skin compared to non-virally injected skin (data not shown). (200x magnification)

Figure 9 shows a bar graph quantifying Mac-1 positive immunostaining in footpad sections taken from WT and LIF KO mice following either AdLacZ or AdLIF injection with or without CFA injection. As described in Example 2, staining was analyzed by multiple optical scans of multiple sections. Quantification of Mac-1⁺ staining reveals that injection of AdLIF inhibited inflammatory cell infiltration caused by CFA. As was apparent from the sections presented in Figures 8A-8H, CFA strongly increased Mac-1 staining in both genotypes, but the induction is stronger in the absence of LIF (KO)($p < 0.05$). Moreover, AdLIF injection suppressed the increases in Mac-1 staining in both genotypes ($*p < .05$). Data are expressed as mean \pm S.E.M.

Figures 10A-10H show photographs of representative sections from non-CFA (A, C, E, G) and CFA-injected (B, D, F, H) footpads immunostained for F4/80 two days after CFA and viral injection. Footpads from WT (A-D) and LIF KO (E-H) were injected with either AdLacZ (A, B, E, F) or AdLIF (C, D, G, H). In both genotypes, CFA elicited an increase in F4/80 staining, and AdLIF reduced this increase. Also noteworthy is that CFA elicited much greater F4/80 staining in the LIF KO than in the WT (B vs. D). No increase in staining was seen in AdLacZ infected skin compared to non-virally injected skin (data not shown). (200x magnification)

Figure 11 shows a bar graph quantifying F4/80 positive immunostaining in footpad sections taken from WT and LIF KO mice following either AdLacZ or AdLIF injection with or without CFA injection. As described in Example 2, staining was analyzed by multiple optical scanning of multiple sections. As was apparent from the

sections presented in Figures 10A-10H, CFA strongly increased F4/80 staining in both genotypes, but the induction was stronger in the absence of LIF (KO). Moreover, AdLIF injection suppressed the increases in F4/80 staining in both genotypes. Data are expressed as mean \pm S.E.M. *p<.05

Figure 12 shows a bar graph disclosing the fold change in expression of mRNA in mouse footpads for several different genes associated with the cytokine cascade induced by CFA. Cytokine mRNAs were measured by RNase protection assay. Cytokines were normalized to GAPDH+L32 in the same lane, and then expressed as ratios to their values from non-CFA-injected footpads. The absence of LIF in the KO resulted in a significant suppression of the CFA-mediated induction of TNF α and IL-6. In contrast, the absence of LIF resulted in enhanced CFA-mediated induction of IFN γ , IL-7, IL-1b, and IL-2R α . Data are expressed as mean \pm S.D. (See Example 2 for more details).

Detailed Description of the Invention

The role of the neuropoietic cytokine leukemia inhibitory factor (LIF) in the regulation of peripheral inflammation and pain has been investigated. Provided herein are methods for modulating inflammation and inflammatory pain hypersensitivity by up-regulating endogenous LIF or administering LIF, biologically active fragments of LIF or agonists of the LIF receptor.

LIF is known in the art and described in Fukada, PNAS, USA, 82:8495 (1985). The gene for the mouse version of LIF is described in Gearing, et al., EMBO J., 6:3995 (1987). LIF is also described in European Patent Application Publication No. 1285448, published May 10, 1988. LIF is also sometimes referred to as cholinergic neuronal differentiation factor, and is also known as human macrophage differentiation inducing factor (DIF).

In a preferred embodiment, LIF is from vertebrates and more preferably from mammals, including rodents (rats, mice, hamsters, guinea pigs, etc.), primates, farm

animals (including sheep, goats, pigs, cows, horses, etc) and in the most preferred embodiment, from humans.

5 The individual that is administered LIF herein is a vertebrate and more preferably a mammal. The individual can be a rodent as described above, a primate, a farm animal as described above, and in the most preferred embodiment, is a human. Preferably, the individual is in need of or in anticipation of need of an anti-inflammatory or pain-reliever or both.

10 Administration of LIF can be in combination with one or more further therapeutic agents and includes simultaneous (concurrent) and consecutive administration in any order. The up-regulation or administration of LIF can occur after induction of inflammation or pain, but preferably occurs prior to or simultaneously with induction of inflammation and/or pain. Induction of inflammation and/or pain can be the result
15 of sports- related activities, hard labor, blister-inducing activities or the undertaking of surgery. LIF can also be administered to an individual having Rheumatoid arthritis to reduce swelling and pain associated with arthritis. Generally, inflammatory disorders include any disorder or condition associated with inflammation, i.e., inflammation of the bowel or any other organ, chemically induced inflammation, inflammation due to
20 fire trauma. Each of these conditions, disorders, injuries or inflictions is encompassed by the phrase insult resulting in inflammation or pain.

In one aspect, an agonist of the LIF receptor is administered wherein the agonist reduces and/or prevents inflammation and/or pain. Such agonists include CNTF,
25 OSM, growth promoting activity, cardiotrophin-1, IL-6 and IL-11. The LIF receptor agonist can be administered in combination with other LIF agonists including LIF or a fragment of LIF. A fragment of LIF can be used in the methods provided herein wherein the fragment is biologically active in that it reduces and/or prevents inflammation and/or pain in accordance with the present disclosure. Methods of
30 identification of pain or inflammation reduction or inhibition is further described below.

Inhibition as used herein refers to any delay in the onset of a condition, particularly inflammation or pain. Reduction as used herein refers to a decrease of at least 10%, and more preferably at least a 25% decrease in activity is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred. The reduction is compared to a control concentration of administration of the biologically active composition, wherein the control concentration can be zero.

Inflammation and pain can be determined in a number of ways. Determinations can be made by measuring IL-1beta and nerve growth factor levels (NGF) wherein an increase in either or both of these factors corresponds to a decrease in LIF anti-inflammatory activity.

In an embodiment provided herein, administration of LIF reduces an elevation of IL-1beta by at least 30%, preferably 40%, more preferably 50%, still more preferably 60% and most preferably 70-100%. The reduction is in comparison to a control having a test concentration of LIF, preferably zero.

In another embodiment herein, administration of LIF reduces an elevation of NGF levels by at least 30%, preferably 40%, more preferably 50%, still more preferably 60% and most preferably 70-100%. The reduction is in comparison to a control having a test concentration of LIF, preferably zero.

In a preferred embodiment NGF and IL-1beta levels are inhibited from rising in response to an inflammatory stimuli. In an embodiment provided herein, IL-1beta levels are inhibited by 60% and NGF levels by 50%.

Inflammation can also be determined by direct measurement in size. Swelling can be directly measured by, for example, measuring the diameter of a limb or other body portion.

In a preferred embodiment, administration of nucleic acid encoding LIF, via a viral

vector, suppresses swelling in response to an inflammatory stimulus. In an embodiment herein, swelling is decreased approximately 45% in a normal individual and approximately 35% in an individual lacking endogenous LIF. The reduction is in comparison with the response to an inflammatory stimulus alone or in response to an inflammatory stimulus plus administration of a control virus.

Another measurement indicating anti-inflammatory activity is the determination of immune cell infiltration, such as the presence of polymorphonuclear neutrophils or macrophages. A decrease in these cell types indicates an anti-inflammatory response and vice versa.

In a preferred embodiment, administration of nucleic acid encoding LIF, via a viral vector, reduces macrophage infiltration in response to an inflammatory stimulus. In an embodiment herein, macrophage infiltration is decreased to 1/7-1/16 of that seen in a normal individual in response to an inflammatory stimulus and 1/3-<1/16 of that seen in an individual lacking endogenous LIF. The reduction is in comparison with the response to an inflammatory stimulus alone or in response to an inflammatory stimulus plus administration of a control virus.

Mechanical and thermal hypersensitivity assays can also be used to determine pain sensitivity. The assays can detect increases and decreases in sensitivity to pain.

In a preferred embodiment herein, mechanical (measured by force) and or thermal sensitivity (measured by withdrawal time) can be reduced 2 fold, and preferably at least 3 fold. The onset of pain is preferably delayed by 25% of time and more preferably 50% or more.

In one embodiment herein an individual is administered LIF in anticipation of pain, independent of an inflammatory inducing agent. In this embodiment, thermal sensitivity measured in withdrawal time can be reduced by at least 1 fold, and preferably by at least 2 fold.

In the examples herein, CFA is used as an inflammatory inducing agent. However, as discussed above, a number of conditions or activities result in inflammation.

5 The LIF, LIF fragments, LIF nucleic acids or LIF receptor agonists of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions. By way of example, LIF is discussed herein. The pharmaceutical compositions can be formed by combining LIF in admixture with a pharmaceutically acceptable carrier vehicle. Therapeutic formulations are prepared for storage by mixing the active ingredient having the desired degree of purity with
10 optional physiologically acceptable carriers, excipients or stabilizers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.

15 Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone, amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides,
20 disaccharides and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronic or PEG. Slow release polymer formulations are particularly preferred. Transdermal formulations are also preferred.

25 The formulations to be used for *in vivo* administration are preferably sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following lyophilization and reconstitution. Therapeutic compositions herein generally are placed into a container having a sterile access port, for example, a vial
30 having a stopper pierceable by a hypodermic injection needle.

5 The route of administration is in accord with known methods, e.g. injection, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional routes, topical administration, or by sustained release systems. Additionally, LIF or nucleic acids encoding LIF can be administered to cells and then transplanted into the individual. The cells can be autogenic, allogenic, syngenic or xenogenic, and are preferably autogenic.

10 Dosages and desired drug concentrations of pharmaceutical compositions of the present invention may vary depending on the particular use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of an ordinary physician. Animal experiments provide reliable guidance for the determination of effective doses for human therapy. In vivo examples are provided herein. Interspecies scaling of effective doses can be performed following the principles laid down by Mordenti, J. and Chappell, W. "The use of interspecies
15 scaling in toxicokinetics" *In* Toxicokinetics and New Drug Development, Yacobi *et al.*, Eds., Pergamon Press, New York 1989, pp. 42-96.

20 Additionally, in an embodiment herein, LIF is modified. Modifications fall into one or more of three classes: substitutional, insertional or deletional. These ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding the LIF protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant LIF protein fragments having up to about 100-150 residues may be prepared by *in vitro* synthesis using
25 established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the LIF protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified
30 characteristics as will be more fully outlined below.

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger. Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances.

Covalent modifications of LIF polypeptides may be made to use in one or more of the methods provided herein. One type of covalent modification includes reacting targeted amino acid residues of an LIF polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N-or C-terminal residues of an LIF polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking LIF to a water-insoluble support matrix or surface for use in the method for purifying anti-LIF antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, *e.g.*, 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimide.

Other modifications include deamidation of glutamyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the α -amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the LIF polypeptide comprises altering the

native glycosylation pattern of the polypeptide. Altering the native glycosylation pattern is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence LIF polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence LIF polypeptide.

5

Addition of glycosylation sites to LIF polypeptides may be accomplished by altering the amino acid sequence thereof. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence LIF polypeptide (for O-linked glycosylation sites). The LIF amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the LIF polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

10

Another means of increasing the number of carbohydrate moieties on the LIF polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

15

Removal of carbohydrate moieties present on the LIF polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).

20

25

Another type of covalent modification of LIF comprises linking the LIF polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

30

Nucleic acids encoding LIF, LIF fragments or LIF receptor agonists may also be used in gene therapy. In gene therapy applications, genes are introduced into cells in order to achieve *in vivo* synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. Gene therapy includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA.

There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells *in vitro*, or *in vivo* in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells *in vitro* include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred *in vivo* gene transfer techniques include transfection with viral vectors, including retrovirus, adenovirus, adeno-associated virus, herpesvirus and poxvirus, and viral coat protein-liposome mediated transfection (Dzau et al., (1993) *Trends in Biotechnology* 11: 205-210; Sandmair AM, et al., (2000) *Adv. Exp. Med. Biol.* 465:423-429; Walther W et al., (2000) *Drugs* 60(2):249-271). Viral delivery of nucleic acids to targets for gene therapy has become standard practice in the art. Direct administration of bare nucleic acid is also possible.

In some situations it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half-life. The technique of receptor-mediated endocytosis is described, for example, by Wu *et al.*, *J. Biol. Chem.* 262, 4429-4432

(1987); and Wagner *et al.*, Proc. Natl. Acad. Sci. USA 87, 3410-3414 (1990). For review of gene marking and gene therapy protocols see Anderson *et al.*, Science 256, 808-813 (1992).

5 In a preferred embodiment, nucleic acids encoding LIF are introduced into cells, preferably *in vivo*. Preferably, the nucleic acids are introduced into cells of an individual using a viral vector. Preferably, said nucleic acid is expressed in cells of the individual to produce the LIF protein. In one embodiment herein, an adenovirus comprising nucleic acid encoding LIF is introduced into an individual and expressed
10 in cells of the individual to produce the LIF protein.

In a preferred embodiment, the LIF proteins, nucleic acids, modified proteins and cells or animal models (which can be knock out (KO) models, i.e. LIF KO models) containing the same are used in screening assays. Identification of modulators or
15 simulators of LIF activity identified as described herein, permits the design of drug screening assays for compounds that modulate or simulate LIF activity. In particular, modulators that enhance the anti-inflammatory and/or pain reduction activity of LIF can be identified and administered to an individual in need thereof in conjunction with or independently LIF. Modulation is a change of about at least 10-30%, preferably
20 40-50%, more preferably at least 50-75%, or most preferably, at least 75-100%. As discussed herein, changes in LIF activity can be determined by identification of changes in pain and/or inflammation responses. Such responses can be determined by identification in changes in the presence of NGF, IL-1beta and immune cell infiltrate as well as mechanical and thermal sensitivity and physical swelling.

25 Screens may be designed to first find candidate agents that can bind to LIF proteins, and then these agents may be used in assays that evaluate the ability of the candidate agent to modulate LIF activity. Thus, as will be appreciated by those in the art, there are a number of different assays which may be run; binding assays and activity assays.

30 Thus, in a preferred embodiment, the methods comprise combining an LIF protein and

a candidate bioactive agent, and determining the binding of the candidate agent to the LIF protein. Preferred embodiments utilize the human LIF protein, although other mammalian proteins may also be used, including rodents (mice, rats, hamsters, guinea pigs, etc.), farm animals (cows, sheep, pigs, horses, etc.) and primates. These latter
5 embodiments may be preferred in the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative LIF proteins may be used, including deletion LIF proteins as outlined above.

Furthermore, included within the definition of LIF proteins are portions of LIF
10 proteins; that is, either the full-length protein may be used, or functional portions thereof. In addition, the assays described herein may utilize either isolated LIF proteins or cells comprising the LIF proteins.

Generally, in a preferred embodiment of the methods herein, the LIF protein or the
15 candidate agent is non-diffusably bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any
20 convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of assays can be carried out simultaneously, using small amounts of reagents and samples. In some cases
25 magnetic beads and the like are included. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the
30 protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. In one

embodiment, gp130 is used. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety. Also included in this invention are screening assays wherein solid supports are not used.

In a preferred embodiment, the LIF protein is bound to the support, and a candidate bioactive agent is added to the assay. Alternatively, the candidate agent is bound to the support and the LIF protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

The term "candidate bioactive agent" or "exogeneous compound" as used herein describes any molecule, e.g., protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide, etc., with the capability of directly or indirectly altering the bioactivity of LIF. Generally a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e., at zero concentration or below the level of detection.

Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or

aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.

5

Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification to produce structural analogs.

10

15

In a preferred embodiment, the candidate bioactive agents are proteins. By "protein" herein is meant at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides and peptides. The protein may be made up of naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures. Thus "amino acid", or "peptide residue", as used herein means both naturally occurring and synthetic amino acids. For example, homo-phenylalanine, citrulline and noreleucine are considered amino acids for the purposes of the invention.

20

"Amino acid" also includes imino acid residues such as proline and hydroxyproline.

25

The side chains may be in either the (R) or the (S) configuration. In the preferred embodiment, the amino acids are in the (S) or L-configuration. If non-naturally occurring side chains are used, non-amino acid substituents may be used, for example to prevent or retard in vivo degradations.

30

In a preferred embodiment, the candidate bioactive agents are naturally occurring proteins or fragments of naturally occurring proteins. Thus, for example, cellular

extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of procaryotic and eucaryotic proteins may be made for screening against LIF. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred.

In a preferred embodiment, the candidate bioactive agents are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, for example, of hydrophobic amino acids, hydrophilic residues, sterically biased (either small or large) residues, towards the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

In a preferred embodiment, the candidate bioactive agents are nucleic acids. By "nucleic acid" or "oligonucleotide" or grammatical equivalents herein means at least

two nucleotides covalently linked together. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, as outlined below, nucleic acid analogs are included that may have alternate backbones, comprising, for example, phosphoramidate (Beaucage et al., Tetrahedron 49(10):1925 (1993) and references therein; Letsinger, J. Org. Chem. 35:3800 (1970); Sprinzl et al., Eur. J. Biochem. 81:579 (1977); Letsinger et al., Nucl. Acids Res. 14:3487 (1986); Sawai et al., Chem. Lett. 805 (1984), Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); and Pauwels et al., Chemica Scripta 26:141 (1986)), phosphorothioate (Mag et al., Nucleic Acids Res. 19:1437 (1991); and U.S. Patent No. 5,644,048), phosphorodithioate (Briu et al., J. Am. Chem. Soc. 111:2321 (1989), O-methylphosphoroamidite linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and linkages (see Egholm, J. Am. Chem. Soc. 114:1895 (1992); Meier et al., Chem. Int. Ed. Engl. 31:1008 (1992); Nielsen, Nature, 365:566 (1993); Carlsson et al., Nature 380:207 (1996), all of which are incorporated by reference). Other analog nucleic acids include those with positive backbones (Denpcy et al., Proc. Natl. Acad. Sci. USA 92:6097 (1995); non-ionic backbones (U.S. Patent Nos. 5,386,023, 5,637,684, 5,602,240, 5,216,141 and 4,469,863; Kiedrowshi et al., Angew. Chem. Intl. Ed. English 30:423 (1991); Letsinger et al., J. Am. Chem. Soc. 110:4470 (1988); Letsinger et al., Nucleoside & Nucleotide 13:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook; Mesmaeker et al., Bioorganic & Medicinal Chem. Lett. 4:395 (1994); Jeffs et al., J. Biomolecular NMR 34:17 (1994); Tetrahedron Lett. 37:743 (1996)) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within the definition of nucleic acids (see Jenkins et al., Chem. Soc. Rev. (1995) pp169-176). Several nucleic acid analogs are described in Rawls, C & E News June 2, 1997 page 35. All of these references are hereby expressly incorporated by reference. These modifications of the ribose-phosphate backbone may be done to

facilitate the addition of additional moieties such as labels, or to increase the stability and half-life of such molecules in physiological environments. In addition, mixtures of naturally occurring nucleic acids and analogs can be made. Alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made. The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid contains any combination of deoxyribo- and ribo-nucleotides, and any combination of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc.

As described above generally for proteins, nucleic acid candidate bioactive agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of procaryotic or eucaryotic genomes may be used as is outlined above for proteins.

In a preferred embodiment, the nucleic acids are antisense to the nucleic acids encoding LIF or a protein or peptide which modulates or is modulated by LIF. Administration of nucleic acids to cells, both *in vitro* and *in vivo* is discussed above.

In a preferred embodiment, the candidate bioactive agents are organic chemical moieties, a wide variety of which are available in the literature.

The determination of the binding of the candidate bioactive agent to LIF may be done in a number of ways. In a preferred embodiment, the candidate bioactive agent is labelled, and binding determined directly. For example, this may be done by attaching all or a portion of the LIF protein to a solid support, adding a labelled candidate agent (for example a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as is known in the art.

By "labeled" herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, e.g. radioisotope, fluorescers, enzyme, antibodies, particles such as magnetic particles, chemiluminescers, or specific binding molecules, etc. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above. The label can directly or indirectly provide a detectable signal.

In some embodiments, only one of the components is labeled. For example, the proteins (or proteinaceous candidate agents) may be labeled at tyrosine positions using ^{125}I , or with fluorophores. Alternatively, more than one component may be labeled with different labels; using ^{125}I for the proteins, for example, and a fluorophor for the candidate agents.

In a preferred embodiment, the binding of the candidate bioactive agent is determined through the use of competitive binding assays. In this embodiment, the competitor is a binding moiety known to bind to the target molecule (i.e. LIF), such as an antibody, peptide, binding partner, ligand, etc. In one embodiment gp130 is used. Under certain circumstances, there may be competitive binding as between the bioactive agent and the binding moiety, with the binding moiety displacing the bioactive agent.

In a preferred embodiment, the competitor is added first, followed by the candidate bioactive agent. Displacement of the competitor is an indication that the candidate bioactive agent is binding to the LIF protein and thus is capable of binding to, and potentially modulating, the activity of the LIF protein. In this embodiment, either component can be labeled. Thus, for example, if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the candidate bioactive agent is labeled, the presence of the label on the support indicates displacement.

In an alternative embodiment, the candidate bioactive agent is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the bioactive agent is bound to the LIF protein with a higher affinity. Thus, if the candidate bioactive agent is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the candidate agent is capable of binding to the LIF protein.

In a preferred embodiment, the methods comprise differential screening to identify bioactive agents that are capable of modulating the activity of the LIF proteins. In this embodiment, the methods comprise combining an LIF protein and a competitor in a first sample. A second sample comprises a candidate bioactive agent, an LIF protein and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the LIF protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the LIF protein.

Alternatively, a preferred embodiment utilizes differential screening to identify drug candidates that bind to the native LIF protein, but cannot bind to modified LIF proteins. The structure of the LIF protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect LIF bioactivity are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, all samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in any order that provides for the requisite binding.

The components provided herein for the assays provided herein may also be combined to form kits. The kits can be based on the use of the protein and/or the nucleic acid encoding the LIF proteins. Assays regarding the use of nucleic acids are further described below.

Screening for agents that modulate the activity of LIF may also be done. In a preferred embodiment, methods for screening for a bioactive agent capable of modulating the activity of LIF comprise the steps of adding a candidate bioactive agent to a sample of LIF, as above, and determining an alteration in the biological activity of LIF. Modulating the activity of LIF can include an increase in activity, a decrease in activity, or a change in the type or kind of activity present. In an embodiment herein, modulating includes inhibition or delay of onset of activity. Thus, in this embodiment, the candidate agent should both bind to LIF (although this may not be necessary), and alter its biological or biochemical activity as defined herein. The methods include both in vitro screening methods, as are generally outlined above, and in vivo screening of cells for alterations in the presence, distribution, activity or amount of LIF.

In a preferred embodiment, the activity of the LIF protein is increased; in another preferred embodiment, the activity of the LIF protein is decreased. Thus, bioactive agents that are antagonists are preferred in some embodiments, and bioactive agents that are agonists may be preferred in other embodiments. Agonists of the LIF receptor and enhancers are preferred. Enhancers act in conjunction with LIF. LIF activity is

described above, wherein pain and/or inflammation can be determined in a number of different ways. Changes in activity indicate a modulator.

In a preferred embodiment, the invention provides methods for screening for bioactive agents capable of modulating the activity of an LIF protein. The methods comprise adding a candidate bioactive agent, as defined above, to a cell comprising LIF proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes an LIF protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

In some embodiments, the assays include exposing the cells to an inflammatory agent that will induce inflammation in control cells, i.e. cells of the same type but that do not contain the exogenous nucleic acid encoding an LIF. Suitable inflammatory agents are known in the art and include but are not limited to CFA or infliction of trauma. Alternatively, the cells may be exposed to conditions that normally result in inflammation, and changes in the normal inflammation progression are determined. Alternatively, the cells can be diseased with an inflammatory disorder or be “knock out” cells as described in the examples. In preferred embodiments, the cells are in an animal model to determine the LIF activity. Alternatively, the cells are in a cell culture taken from an animal model. Thus, the effect of the candidate agent on LIF activity is then evaluated.

The specific examples herein show that levels of LIF mRNA are increased by an inflammatory inducing agent. Also provided are the results of two types of perturbation experiments. LIF levels were either raised acutely through local injection of LIF or they were lowered chronically through the use of mice that lack a functional LIF gene. LIF is shown to suppress inflammation in a LIF knockout mouse, where the response to the inflammatory agent involves edema, higher levels of inflammatory cytokines and more cellular infiltrate.

Several results from the converse experiment, injecting LIF just prior to the

inflammatory inducing agent, are also provided herein. For instance, LIF injection at a single time point prior to inflammation has an analgesic action. Moreover, LIF pretreatment diminishes the rise in IL-1 β and NGF induced by the inflammatory inducing agent.

5

Results are also provided wherein an inflammatory agent is not administered after the administration of LIF. Thermal sensitivity was significantly reduced in this embodiment.

10

In addition, results are provided herein to show that intradermal administration of LIF nucleic acid, via a viral vector, resulted in local expression of LIF in dermal cells. Such administration concurrent with administration of an inflammatory inducing agent suppressed edema and suppressed inflammatory cell (macrophage) infiltration to the insulted tissue. This administration of LIF nucleic acid also regulated the expression of several cytokines associated with inflammation.

15

The results provided herein show that administration of LIF, biologically active fragments of LIF or other agonists of the LIF receptor can modulate inflammation and pain.

20

All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.

25

The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

SPECIFIC EXAMPLES

EXAMPLE 1

30

Methods:

Animals. Experiments were performed on adult male Sprague-Dawley rats

(200-250g), as well as wild type (WT) and LIF-deficient mice (Stewart CL, et al, (1992) *Nature* 359:76-79). The mutant mice were maintained by mating within the original colony of the mutant strain, or by back crossing with the C57Bl6 parental strain. All of the data reported here on mutant mice comes from the former matings.

5 Null mutants were produced by mating heterozygotes or by mating null males with heterozygote females. Nulls, heterozygotes and WT mice were compared as littermates.

10 A PCR-based method was used to determine the genotype of the mice. Genomic DNA was isolated from tail biopsies using a spin column DNA isolation kit (Quiagen, Chatsworth, CA) and 50-100 ng was subjected to PCR amplification (40 cycles: 1 cycle of 5 min. 95°C, 45 sec. 68°C, 45 sec. 72°C; 38 cycles of 30 sec. 95°C, 45 sec. 68°C, 45 sec. 72°C; and 1 cycle of 30 sec. 95°C, 45 sec. 68°C, 3 min. 72°C). Two specific DNA fragments were co-amplified: a 192 bp LIF gene fragment (using a LIF sense primer, 5'-cgcctaacaatgacagacttcccat-3', and a LIF antisense primer, 15 5'-aggccccctcatgacgtctatagta-3') and a 541 bp neomycin gene fragment (using a Neo-sense primer, 5'-ccagctcttcagcaatatcacggg-3', and a Neo-antisense primer, 5'-cctgtccggtgccctgaatgaact-3'). The reaction mixture contained 1 x PCR buffer (10 mM TrisCl pH = 8.3, 50 mM KCl and 0.001% gelatin), 2.5 mM MgCl₂, 0.1 mM dNTPs, 0.1 U/μl *Taq*-polymerase (Promega, Madison, WI) and 0.4 pmol/μl primers 20 (each) in a total volume of 15 μl. The amplification products (4 μl) were separated in a 1.5% agarose gel prestained with ethidium bromide, and analyzed on a UV transilluminator. LIF WT mice contained only the LIF product (192 bp), the heterozygotes had both bands (192 and 541 bp), and the LIF-deficient mice had only 25 the larger fragment (541 bp).

Behavior. Thermal and mechanical sensitivity of the rat hindpaw were tested as previously described in detail (Woolf CJ, et al, *J Neurosci* 16:2716-2723). Response time (foot withdrawal) on exposure to a hot plate (50°C) was measured as an index of 30 sensitivity to a noxious thermal stimulus, while the mechanical threshold for eliciting a flexion withdrawal response was measured in grams using calibrated monofilament

Von Frey hairs (4.1 - 72g). The response of 3 applications of a particular Von Frey hair to the dorsal surface of the foot was tested in each case.

5 *LIF injections.* Recombinant human LIF (Preparation 93/562, 1 mg = 10000 units; National Institute for Biological Standards and Control, UK) was dissolved in saline at concentrations of a 100 or 1000 ng/ml and injected into the hindpaw under halothane anesthesia (2%) in a volume of a 100 μ l.

10 *Inflammation.* A unilateral acute inflammatory lesion was produced in rats by an injection into the plantar surface of the hindpaw, under halothane anesthesia (2%), of 100 μ l complete Freund's adjuvant (Sigma). In some animals 10 or 100 ng LIF was injected into the dorsal and plantar surfaces of the hindpaw 10 minutes before the CFA injection. In another group of animals LIF was injected 48 hours after CFA administration into the plantar and dorsal surfaces of the hindpaw. For mice, 20 μ l of
15 CFA (Sigma) was injected into the left hind hindpaw under ether anesthesia.

20 *LIF, IL-1 β and NGF assays.* Under deep terminal anesthesia (pentobarbital) samples of hindpaw skin, sciatic nerve and L4 and L5 dorsal root ganglia (DRG) were dissected free, weighed, frozen on dry ice and stored at -80°C. The tissue was sampled for LIF mRNA, IL-1 β and NGF using an RNase protection assay for the first and ELISAs for the second two.

25 *RNase protection assay.* Total RNA was extracted from footpad skin by a standard acid-phenol method. RNA was resuspended in H₂O and stored at -70°C until use. The structural integrity of the RNA was confirmed with non-denaturing agarose gel electrophoresis. RNase protection was performed as previously described (Banner, LR, Patterson, PH (1994) *Proc Natl Acad Sci USA* 91:7109-7113), with slight modification of the probe synthesis. Ninety mCi of 32P-GTP (LIF) or -UTP (glyceraldehyde phosphate dehydrogenase; GAPDH) was dried in a 1.5 ml eppendorf
30 tube. The LIF probe was as previously described (Banner, LR, Patterson, PH (1994) *Proc Natl Acad Sci USA* 91:7109-7113) and radioactivity was quantitated by scanning

the protected fragments on a Phosphorimager 400S (Molecular Dynamics). The intensity of the radioactive signal emitted by the LIF-protected fragment was compared to the GAPDH-protected fragment as an internal control for the steady-state amount of RNA, and the values expressed in arbitrary units. We have previously shown that GAPDH mRNA levels do not vary in response to injury and thus serves as a good internal control for steady-state RNA levels (Banner, LR, Patterson, PH (1994) *Proc Natl Acad Sci USA* 91:7109-7113).

IL-1 β and NGF ELISAs. The tissue was homogenized in phosphate buffered saline (PBS) containing; 0.4M NaCl, 0.05% Tween 20, 0.5% bovine serum albumin (BSA), 0.1 mM phenylmethylsulfonyl fluoride, 0.1 mM benzethonium chloride, 10 mM EDTA and 20 KI/ml Aprotinin (Sigma) and the supernatant collected for assay. NGF was measured with a two-site enzyme-linked immunoassay (ELISA) as described before (Safieh-Garabedian B, *Br J Pharmacol* 115:1265-1275) using a polyclonal rabbit anti-mouse NGF antiserum raised in our laboratory for coating and a monoclonal antibody (23c4) (Weskamp G, Otten U (1987) *J Neurochem* 48:1779-1786) for detection. An HPLC-purified mouse NGF preparation was used as standard (Promega). IL-1 β was measured with a two-site ELISA as previously described (Safieh-Garabedian B, *Br J Pharmacol* 115:1265-1275) using immunoaffinity purified sheep polyclonal anti-rat IL-1 β antibodies. Recombinant rat IL-1 β was used as the standard (provided by Dr. Robert Newton, DuPont-Merck). Results are expressed as ng/hindpaw to deal with the changes in weight of inflamed skin.

Paw diameter. The dorso-ventral thickness of the hindpaw was measured in deeply anesthetized (pentobarbital) animals using a micrometer gauge.

Statistical analysis. Results are presented as mean \pm SEM. Differences were calculated using Student's or Welch's t test, analysis of variance (ANOVA) followed by Dunnet's Multiple Comparison test, or the Mann-Whitney U-test, where appropriate.

Results:

Induced inflammation increases LIF mRNA levels

LIF mRNA levels are altered upon induction of inflammation. Six hours after induction of an acute inflammation of the rat hindpaw by intraplantar injection of CFA, LIF mRNA levels were measured by an RNase protection assay and expressed as a ratio with GAPDH mRNA. LIF mRNA is elevated in the inflamed skin at 6 hours (4.1 ± 1.8 ipsilateral, 2.8 ± 1.1 contralateral, from naive levels of 1.0; LIF/GAPDH \pm SEM, n=4), and the trend is a further increase at 48 hour (5.7 ± 2.1 ipsi, 1.4 ± 0.3 contra). The maximal mean relative increase in LIF is 5.7-fold. Smaller, transient increases observed on the contralateral side have been noted for other proteins in this and similar models (Woolf CJ, et al, *Br J Pharmacol* 121:417-424). A smaller bilateral change also occurs in the sciatic nerve (2.43 ± 1.10 ipsilateral, 1.86 ± 0.38 contralateral, from naive levels of 1.0; LIF/GAPDH \pm SEM, n=4, 6 h post CFA). In the ipsilateral L4 and L5 DRG, the LIF/GAPDH value in naive animals is 0.53 ± 0.14 and this increases slightly to 0.88 ± 0.23 at 6 hours post CFA injection.

Inflammation is greater in LIF knockout mice

A stringent test of whether LIF is required for either the development of, or recovery from inflammation is to determine the effects of CFA injection in LIF knockout mice. The general appearance and behavior of WT and LIF knockout mice are similar although the latter are slightly smaller. There is, however, a very significant difference in the response of the two strains to CFA injection. Four hours post-CFA administration, the hindpaws in the mutant mice are very swollen. At 24 and 48 hours the swelling spreads past the ankle and up the calf, and the skin of the foot is under marked tension. In WT mice at these time points, inflammation is limited to the hindpaw and is much less prominent. The difference in dorso-ventral paw diameter at 48 hour post-CFA injection is quantified for the two strains and presented in Figure 1C. The mean percentage increase in paw diameter is more than twice as great in the LIF knockout mice ($p < 0.01$).

Another assay for inflammation involves quantification of cytokines and growth factors that are elevated under a variety of inflammatory conditions. We find that CFA injection induces a 2-fold elevation in IL-1 β at 24 hour in WT mice (from naive levels of 564 ± 27 pg/hindpaw to 1068 ± 63 pg/hindpaw, n=5). In LIF knockout mice, however, the IL-1 β levels at 48 hours post CFA are 1712 ± 364 pg/hindpaw (n=5). When the data are expressed as a ratio of the levels in the inflamed (ipsilateral) and non-inflamed (contralateral) hindpaws at 48 hours, the relative difference is 2-fold in the WT and 9-fold in the mutant mice (Figure 1A). A similar relative change is detected for NGF levels in the hindpaw, with a significantly greater ratio in mutant versus WT animals (Figure 1B). At 48 hours the NGF levels in the WT mice are 94.6 ± 10 pg/hindpaw (n=5) while in mutant mice the levels are 186 ± 46 pg/hindpaw (n=5).

Analysis of the cellular infiltrates in WT and LIF mutant mice reinforce these findings. Staining of the skin 48 hours post-CFA reveals not only a much thicker dermis in the mutants, but many more densely labeled neutrophils (Figure 2). This difference was quantified by counting cells in 9 sections from 3 animals of each genotype. The LIF mutant mice have 4.75-fold more neutrophils in the inflamed dermis than the WT (+/+, 40.2 ± 7.1 ; -/-, 190.0 ± 15.1 ; n=9). When expressed as a density of neutrophils per 100 μ m, the mutants have more than twice as many cells as the WT (+/+, 8.58 ± 0.24 ; -/- 20.83 ± 1.54 ; $p < 0.005$). The mutants also have >2 fold more mast cells than the WT.

Sensitivity to mechanical and thermal stimulation

To test whether endogenous LIF acts as an anti-inflammatory agent, we injected LIF into the rat hindpaw 10 minutes before induction of inflammation with CFA. Injection of 100 ng LIF into plantar and dorsal surfaces preceding CFA has a marked effect. Both mechanical and thermal sensitivity in the early phase of inflammation are substantially reduced (Figures 3A and 3B). Maximal LIF-induced analgesia in both assays is observed 3 hours post-CFA injection ($p < 0.001$). An effect of LIF on thermal sensitivity is also apparent at 48 hour ($p < 0.01$). Thus, injection of LIF at a

single time point has significant consequences for the subsequent rate and extent of pain associated with inflammation. Also see Figure 5.

Consistent with its analgesic effects, LIF injection reduces the induction of IL-1 β and NGF stimulated by CFA (Figures 4A and 4B). Moreover, injection of LIF delays paw swelling and has some affect on reduction in size: 3 hours following CFA treatment the dorsoventral paw diameter increases by $28 \pm 6\%$ (n=4) while in the LIF (100 ng) + CFA group this increase is $25 \pm 4\%$ (n=4).

It is presumed that LIF exerts its anti-inflammatory, analgesic effects via the Jak-STAT pathway (Inoue M, et al, (1996) *Molec Neurobiol* 12:195-209). Directly or indirectly this leads to the inhibition of the transcription or release of pro-inflammatory cytokines such as IL-1 (Figure 1, 4B), or to the release of an anti-inflammatory agent such as IL-1RA (Dinarello CA (1996) *Blood* 87:2095-2147). Regarding upstream activators of LIF, TNF α induces LIF in dermal and chondrocyte cultures (Campbell et al, (1993) *Arthritis Rheum* 36:790-794; and Lorenzo JA, et al, *Clin Immunol Immunopathol* 70:260-265), and anti-TNF antibodies attenuate LIF levels in the circulation in primate sepsis (Jansen, PM, et al, (1996) *J Immunol* 156:4401-4407).

Our findings show that LIF is a protective cytokine which is induced early during inflammation and which suppresses expression of cytokines and growth factors that contribute to the inflammatory response and pain. These results indicate that inflammation and pain can be modulated by administration or regulation of LIF and other agonists of the LIF receptor.

The results herein also support that regulation of the gp130 signal transducing subunit utilized by the neuropoietic cytokine family can be used to modulate inflammation and/or pain.

EXAMPLE 2

Since contradictory conclusions have been made regarding the role of LIF in cutaneous inflammation, we have revisited this issue using the additional technique of viral delivery of LIF, and also using an additional measure of inflammation, the expression of 11 relevant cytokines. The latter data is particularly useful, as no such information is apparently available for the CFA model. It is also important to investigate the potential utility of viral gene therapy in an animal model of cutaneous inflammation, particularly given the relative ease of using this technique with skin and the importance of this clinical problem.

Methods:

Mice. The strain of LIF KO (-/-) mice used in this work was that of Stewart et al. (1992) *Nature* 359: 76-79), which has been intermittently backcrossed with the C57BL/6 strain to maintain fertility and viability. Genotypes were determined by the polymerase chain reaction (Banner L, et al., (1998) *J. Neurosci.* 18: 5456-5462), and all comparisons were made only among mice of the same age. All animal procedures conformed to the requirements of the Caltech Research Animal Care and Use Committee.

Adenovirus construction. The adenoviral vector was derived from adenovirus serotype 5 deleted of its E1 and E3 regions. Recombinant adenovirus containing LacZ (AdLacZ) , LIF (AdLIF) or no transgene (AdPacI) were constructed with the transgene under the control of the cytomegalovirus promotor. The 293 cells expressing the E1A and E1B proteins support the replication of E1A-defective mutants (obtained from N. Davidson's laboratory at Caltech) and were maintained in DMEM (GIBCO) containing 2% fetal calf serum. Following infection, cells were harvested, resuspended in culture medium, and subjected to three rounds of freezing and thawing. Cell debris was eliminated by centrifugation at 3000Xg, at 4° C for 15 min. Crude viral supernatants were layered on a discontinuous CsCl gradient and centrifuged for 2 hr at 36,000 rpm. Isolated viral particles were then subjected to a second round of CsCl centrifugation. Viral particles were collected, dialyzed against

buffer containing 10 mM HEPES pH 7.5, 140 mM NaCl, 1mM MgCl, and 10% glycerol, aliquoted, and frozen at -80° C. Viral titers were assayed by plaque assay on 293 cells and expressed as plaque forming units (pfu)/ml.

5 *Assay of LIF expression by adenovirus.* Confluent rat skin fibroblasts were prepared from dorsal skin of adult rats by standard methods (Maquart FX, et al., (1980) *Biochimie* 62: 93-97). Small pieces of dermis (1-3 mm³) were explanted to 60 mm dishes and incubated in DMEM for 7-10 days. Fibroblasts growing out on the dish were harvested with 0.05% trypsin and sub-cultured in 24 well plates for up to 10
10 passages. Cells were infected with virus at 37 °C for 2 hr and then washed with DMEM. Wells were incubated with 250 ml DMEM for 1-3 days. This conditioned medium (100 ml) was incubated on M1 cells (5 x 10² cells/well) in 96 well microtiter plates for 3-7 days. Cell number was assayed by the MTT method (Mosmann T (1983) *J. Immunol. Meth.* 65: 55-63).

15 *In vivo gene transfer.* Mice were anesthetized with isoflurane. Viral stocks of AdPacI, AdLacZ and AdLIF were thawed and diluted in PBS (1mM Ca⁺⁺ +1mM Mg⁺⁺), and a final volume of 10ml (3X10⁹ particles) was injected intradermally with a Hamilton microsyringe (# 80301) and a Hamilton needle (# 90033; Reno, Nevada) into the skin
20 of the footpad.

CFA-induced inflammation. An acute inflammatory lesion was produced by injection into the plantar surface of the hindpaw, under isoflurane anesthesia, of 20 ml of CFA (1 mg/ml mycobacterium tuberculosis (H37Ra, ATCC 25177) in 0.85 ml of paraffin
25 oil and 0.15 ml of mannide monooleate; Sigma, St. Louis, MO). Edema was assayed by measuring paw diameter using calipers applied across the dorsoventral midplane of the hindpaw.

Histochemical staining for β -galactosidase. Footpads were removed from mice
30 following perfusion with PBS buffer and then 2% paraformaldehyde, post-fixed with 2% paraformaldehyde for 30 min, and then immersed in 30% sucrose in PBS

overnight prior to OCT-embedding. Frozen sections of 10 mm were taken at multiple levels through the block. Following immersion in X-Gal reagent (5mM $K_3Fe(CN)_6$, 5mM $K_4Fe(CN)_6$, 25mM $MgCl_2$, 2mg/ml X-Gal; Roche Molecular Biochemicals, Indianapolis, IN) for 4hr at 37°C, sections were counterstained with eosin and examined by light microscopy.

Double staining for LIF protein and β -galactosidase. Sections stained with X-Gal reagent were blocked with 2% swine serum for 2hrs at RT, and then immunostained overnight at 4⁰ with polyclonal, goat anti-LIF antibodies (R& D Systems) at 1:2000 dilution in 2% swine serum in PBS. Biotinylated swine, anti-goat IgG (Roche) was then applied for 2hr at RT. Slides were mounted with Permount and examined by light microscopy.

Analysis of cellular infiltration. Macrophages were identified by immunostaining with the Mac-1 and F4/80 antibodies (BioSource International; Camarillo, CA). Frozen sections were rinsed 3 times in PBS at RT and endogenous peroxidase was blocked with 3% H_2O_2 in PBS for 10 min at RT. Nonspecific antibody binding was blocked with 2% normal rabbit serum (Sigma, Saint Louis, MO) for 2hr. The primary antibodies were diluted with 2% normal rabbit serum in PBS (1:2500 for MacI and 1:250 for F4/80) and applied to sections overnight at 4⁰. Sections were incubated with biotinylated rabbit, anti-rat IgG at 1:200 dilution for 1 hr, followed by the developing solutions from the ABC Kit and substrate VIP kits (Vectastain Elite ABC Kit™, Vector Laboratories, Inc; Burlingame, CA). Immunostaining was quantified by optically scanning photographs using frames placed in the AdLIF or AdLacZ injection sites. Four frames were used for each section and 3 sections were used per footpad. Data from 4 footpads of 2 mice of each group were used to calculate the mean and S.E.M. Background optical density outside of the skin tissue was subtracted from each frame before quantification.

RNase protection assay. Footpad skin was removed under deep terminal pentobarbital anesthesia, and total RNA extracted by the single-step method (16). Total RNA from

two feet of the same mouse was treated as one sample. Three mice were used for each group. Multiprobe template mCK-3b and mCK-L (custom template sets; PharMingen, San Diego, CA) contained DNA templates for the following cytokines: TNF α and b, IL-6, INF γ , TGF β 1, b2 and b3, IL-12p32 and p40, IL-7, IL-1 α , IL-1 β , IL-1RA (IL-1 receptor antagonist), LIF, IL-2R α , and the housekeeping genes L32 (ribosomal RNA) and glyceraldehyde phosphate dehydrogenase (GAPDH). The assay was performed according to the manufacturer's protocol. Briefly, DNA templates were used to synthesize probes, which were labeled with α -[32 P]UTP (3,000 Ci/mmol, 10mCi/ml; DuPont NEN Research Products, Boston, MA), in the presence of a GACU pool using a T7 polymerase. Each probe was hybridized overnight at 56°C with 15-20 mg of total RNA, followed by digestion with RNase A and T1. The samples were then treated with proteinase K-SDS mixture, extracted with phenol-chloroform, and precipitated in the presence of ammonium acetate. Samples were loaded on an acrylamide-urea sequencing gel, with undigested labeled probes, and run at 50W with 0.5' TBE for 2.5 hrs. The gel was dried on filter paper under vacuum. For quantitation, the dried gel was placed in a Phosphorimager (Molecular Dynamics, Sunnyvale, CA) cassette and exposed to a Kodak Storage phosphor screen at RT for 1-2 weeks. This screen was scanned with a QuantiScan sensitometer, and analysis was done with ImageQuant (Molecular Dynamics, Sunnyvale, CA) software. Background optical density in the same lane (obtained from a frame of the same size) was subtracted from the cytokine band and the resulting value was expressed as a ratio to L32 and GAPDH.

Results:

Characterization of the LIF adenovirus

The AdLIF and AdLacZ viruses were produced as described above, and tested for LIF activity using the M1 cell assay. Recombinant LIF at 10 ng/ml inhibits growth 68%, while supernatants from cells infected with AdLIF and AdLacZ inhibit growth 44% and 4%, respectively. In a similar experiment, we found that an anti-LIF antibody is able to block this activity.

In addition, anti-LIF antibodies stain dermal cells in the skin of the footpad 4 days

following infection with AdLIF and AdLacZ (Fig. 1C) but not following infection with AdLacZ alone (Fig. 1D). To confirm infection by the latter virus, sections were stained for β -galactosidase and are positive (Fig. 1A). We were also able to independently localize viral infection in the case of AdLIF by co-infecting with AdLacZ, and double-staining sections for LIF and β -galactosidase (Fig. 1C). As expected, both viruses infect the same localized area, and in a minority of cases, single cells stain for both proteins.

Endogenous and exogenous LIF suppress edema

In order to determine the optimal time frame in which to study cutaneous inflammation in this CFA model, edema as well as Mac1 and F4/80 staining of macrophages was quantified in WT mice 6 hrs, and 1, 2, 3 and 6 days following CFA injection. The peak of edema and F4/80 staining is clearly at 2 days, while peak Mac1 staining is nearly equivalent at 1 and 2 days (data not shown). Therefore, the 2 day time point was chosen for subsequent experiments.

Injection of CFA increases footpad thickness 55% in WT and 92% in the LIF KO (Fig. 2). This result is very similar to the two-fold difference seen in Example 1, indicating that endogenous LIF suppresses the edema induced by CFA. In this experiment, the controls were injected with AdLacZ virus as well as CFA, in order to control for effects of viral infection in the AdLIF experiments. Additional experiments showed, however, that injection of AdLacZ causes no additional swelling, with or without CFA injection (data not shown). Infection with AdLIF at the same time as CFA results in suppression of the swelling response to CFA, both in the WT and the KO. In the WT, the exogenous LIF suppresses swelling by approximately 45%, and in the KO, exogenous LIF suppresses swelling by about 35%. Both of these differences are significant (Student's t test, $p < .001$; $n = 4$).

Endogenous and exogenous LIF suppress inflammatory cell infiltration

To assess macrophage infiltration following CFA injection, sections were stained with Mac-1 and F4/80. Injection of CFA increases Mac-1 staining approximately 5-fold in

the WT and 7-fold in the LIF KO (Figs. 3 and 4). This difference between the genotypes in their response to CFA was observed in Example 1 in the absence of AdLacZ infection. Injection of AdLIF suppresses the CFA-induced increase in Mac-1 staining in both genotypes; in the WT the increase with CFA in the presence of AdLIF is only about 1/7 of normal, and about 1/3 in the KO with AdLIF ($p < .05$). As a control for the viral infection in the AdLIF experiments, the controls were also injected with AdLacZ. No difference in Mac-1 or F4/80 staining was observed with AdLacZ infection when compared to paired footpads, with or without CFA (data not shown).

Very similar results were obtained for F4/80 staining, which is thought to be more specific for macrophages than Mac-1. Injection of AdLIF suppresses the CFA-mediated induction of F4/80 approximately 4-fold in the WT and over 4-fold in the KO (Figs. 5 and 6). These differences are significant ($p < .05$). Thus, exogenous LIF, delivered simultaneously with CFA, effectively suppresses inflammatory cell infiltration, nearly to background levels.

LIF regulates the cytokine cascade during cutaneous inflammation

To further assess the role of LIF in this paradigm, we assayed the mRNAs for a variety of cytokines and their receptors. This was done in both WT and KO footpads, with and without CFA injection. The results are expressed as the fold-induction of each cytokine caused by CFA. Although this type of data has not been previously published for this paradigm to our knowledge, we predicted that CFA would increase the levels of pro-inflammatory cytokines. Indeed, in the WT footpads, CFA strongly induces IL-6 ($p < 0.03$), and induces other pro-inflammatory cytokines such as TNF α ($p < 0.08$), IL-1b ($p < 0.01$) and the receptor for IL-2 (IL-2R α) ($p < 0.03$) to a lesser degree (Fig. 7). Interestingly, CFA lowers the level of IFN γ ($p < 0.05$), a pro-inflammatory cytokine, and raises the levels of the anti-inflammatory cytokine TGF β 1 ($p < 0.03$). It may be that at this 2 day time point, the anti-inflammatory response has begun to restore the normal state of the tissue. The other apparent effects of CFA on cytokine expression in the WT (TNF β , TGF β , TGF β 3, IL-7, IL-1a,) are not statistically significant. The p values given here represent comparisons of cytokine

mRNA levels in the presence and absence of CFA to those in WT, where n=3 for each.

Regarding the role of LIF in this cascade, we find that CFA induces a significantly larger IL-1b response in the LIF KO than in the WT ($p<.05$), which reproduces our earlier finding on IL-1b protein (12). Moreover, in the absence of LIF, the increases in IL-2R α ($p<.02$) and IL-7 ($p<.04$) are greater than in the WT, and the CFA-induced suppression of IFN γ ($p<.001$) is turned into an increase in the absence of LIF. These results are consistent with an anti-inflammatory role of endogenous LIF. Surprisingly, however, the CFA-induced increase in IL-6 ($p<.03$) is much less in the LIF KO than in the WT (Fig. 7). This strong effect is considered further in the Discussion. Clearly, in the CFA model, the endogenous LIF response to CFA regulates a number of important cytokines and their receptors.

The present results with the LIF KO mouse confirm those described in Example 1, showing that CFA-induced edema and inflammatory cell infiltration are more severe in the absence of endogenous LIF. Example 1 also showed that injection of recombinant LIF protein reduced the CFA-mediated induction of IL-1b and nerve growth factor, but this injection was not very effective at suppressing edema (12). The present approach of raising LIF levels via an adenoviral vector is more efficacious, reducing swelling in the WT by almost half, as well as very strongly suppressing inflammatory cell infiltration and pro-inflammatory cytokine levels. This result may be surprising in view of the fact that only a small minority of skin cells were obviously infected by the virus, and production and release of LIF would be delayed in comparison to the injection of LIF protein itself. The relative effectiveness of the viral approach may be due to its longer lasting effects relative to an injected protein. We have found strong anti-LIF staining for at least 2 weeks following delivery of AdLIF to the brain (K. Oishi, S.C. Lee and P.H. Patterson, unpublished). The use of an adenoviral vector in this context is not without potential problems, however, as there are reports of a similar virus causing an inflammatory reaction (Smith GM, et al., (1999) *J. Neurosci. Res.* 55: 147-157). Under the conditions used here, we did not observe any evidence of such a reaction to either the AdLacZ or the AdPac1, and the AdLIF construct suppressed inflammation

rather than inducing it. This lack of obvious response to the control vectors could be due to the relatively low levels of virus used in these experiments

Our findings that both endogenous and exogenous LIF are anti-inflammatory in the skin are inconsistent with results reported by others. As mentioned in the background, Injection of high doses of LIF into the ear pinnae of mice increased ear thickness (McKenzie RC, et al., (1996) *Acta Derm. Venereol. (Stockh)* 76: 111-114), injection of high concentrations of LIF into skin or joints can induce swelling and leukocyte invasion (Carroll GJ, et al., (1995) *J. Interferon. Cytokine Res.* 15: 567-573; McKenzie RC, et al., (1996) *Acta Derm. Venereol. (Stockh)* 76: 111-114) and systemic injection of high levels of LIF induced a prolonged hypersensitivity to mechanical stimulation (Thompson SWN, et al., (1996) *Neuroscience* 71: 1091-1094). We have also found that injection of low amounts of LIF into the footpad is analgesic (Example 1). It may be that exogenous LIF displays a biphasic dose dependence in peripheral inflammation, with low doses, which likely correspond to endogenous levels induced by injury, being anti-inflammatory (Gadient R, et al., (1999) *Stem Cells* 17: 127-137). It is also worth noting that within the peripheral and central nervous systems, LIF is strongly pro-inflammatory, inducing inflammatory cell infiltration, microglial and astrocyte activation and neuronal injury responses (Gadient R, et al., (1999) *Stem Cells* 17: 127-137; Sugiura S, et al., (2000) *Eur. J. Neurosci.* 12: 457-466). It may be that the skin contains a cell type not present within the nervous system, and this cell may respond to LIF by producing a strong anti-inflammatory agent.

We compared the responses of a variety of cytokines and their receptors to CFA in WT versus LIF KO skin. These data show that LIF is an important regulator of IL-1b, IL-2R α , IL-6, IL-7, and IFN γ . While there were no previous data available on cytokine expression in the CFA skin model, considerable work has been done on cytokine changes in other forms of cutaneous inflammation, particularly psoriasis (Ullrich S.E. (1995) *Photochem. Photobiol.* 62: 389-401; Asadullah K, et al., (1999) *Drugs of Today* 35: 913-924; Bonifati C, et al., (1999) *Int. J. Dermat.* 38: 241-251; Corsini E, et al., (2000) *Toxicology* 142: 203-211; Naik SM, et al., (1999) *J. Invest. Dermatol.* 113:

766-772). A number of type 1 cytokines are up-regulated, including IL-2, IL-6, IL-8, IL-12, IL-18, IFN γ and TNF α . In contrast, relatively low levels of anti-inflammatory cytokines such as IL-1RA and IL-10 have been found in this chronic condition. Perturbation of endogenous cytokines or application of exogenous cytokines has been used to assess their relative roles. In a study of the role of endogenous IL-10 in cutaneous wound healing, it was shown that local injection of an anti-IL-10 antibody caused increased inflammatory cell infiltration and increased levels of chemokines and pro-inflammatory cytokines (Sato Y, et al., (1999) *Biochem. Biophys. Res. Commun.* 265: 194-199). Transgenic mice over-expressing IL-1 α in keratinocytes exhibit spontaneous skin disease and focal inflammatory lesions (Groves RW, et al., (1995) *Proc. Natl. Acad. Sci. USA* 92: 11874-11878). Injection of IL-12 can overcome UV-induced immune suppression, and this cytokine can overcome or reverse superantigen-induced suppression (Schmitt DA, et al., (1995) *J. Immunol.* 154: 5114-5120; Saloga J, et al., (1998) *Immunology* 93: 485-492). Local injection of IL-1 β , but not IL-1 α or TNF α , mimicked cytokine changes induced by allergen, and injection of anti-IL-1 β antibodies prevented sensitization to allergen (Enk AH, et al., (1993) *J. Immunol.* 150: 3698-3704). Notably, preliminary clinical trials have reported amelioration of psoriatic lesions and suppression of pro-inflammatory cytokines upon local application of IL-10 (Asadullah K, et al., (1998) *J. Clin. Invest.* 101: 783-794) or IL-11 (Trepicchio WL, et al., (1999) *J. Clin. Invest.* 104: 1527-1537). The latter result can be viewed as very consistent with our results, as IL-11 and LIF belong to the same cytokine family and induce the same signaling cascades. It has not yet been shown, however, that the receptors for LIF and IL-11 are on the same cells in human or mouse skin. The targets and sources of these cytokines in cutaneous inflammation is an area that deserves more attention.

The roles of IL-1 and TNF have also been investigated in their respective receptor KO mice. The skin of such mice does not display serious abnormalities in their responses to organic solvent, detergent or mechanical disruption (Man M-Q, et al., (1998) *Exp. Dermatol.* 8: 261-266), despite the fact that levels of these cytokines are normally increased by such treatments. In contrast, IL-7 is a keratinocyte-derived growth factor

important for the development of gdT cells including mouse dendritic epidermal T cells (DETC)(Maki K, et al., (1996) *Proc. Natl. Acad. Sci. USA* 93:7172-7177). Expression of this cytokine is increased in psoriasis (Bonifati C, et al., (1997) *Clin. Immunol. Immunopathol.* 83: 41-44), and injection of an anti-IL-7 antibody inhibits
5 gdT cell accumulation in lymph nodes following skin sensitization (Dieli F, et al., (1997) *Eur. J. Immunol.* 27: 206-214; Wang B, et al., (1999) *J. Leukocyte Biol.* 66: 33-39). Moreover, transgenic mice over-expressing IL-7 in keratinocytes develop a lymphoproliferative skin disease (Samaridis J, et al., (1991) *Eur. J. Immunol.* 21: 453-460; Uehira M, et al., (1998) *J. Invest. Dermatol.* 110: 740-745; Mertsching E, et al.,
10 (1995) *Int. Immunol.* 7: 401-414; Williams I, et al., (1997) *J. Immunol.* 159: 3044-3056). Our finding that IL-7 is up-regulated by CFA and that LIF suppresses this is therefore of added interest.

In view of our findings that IL-1 β , IL-7, IFN γ and IL-2R α are all increased in absence
15 of LIF, it is surprising that the response of IL-6 to CFA is reduced in the LIF KO. This is not consistent with the view of IL-6 being pro-inflammatory and LIF exerting anti-inflammatory effects in this model. We found previously that endogenous IL-6 and LIF are each pro-inflammatory in brain injury, but that the double KO did not exhibit a more pronounced phenotype than the single KOs (Sugiura S, et al., (2000) *Eur. J. Neurosci.* 12: 457-466). We suggested that rather than acting in redundant, parallel
20 pathways, these two cytokines may be acting in series, in the same pathway, one controlling the expression of the other. Our present result in cutaneous inflammation can be viewed as consistent with this notion, suggesting an anti-inflammatory role for IL-6. Supporting this hypothesis is the result from a model of skin damage with UVB
25 irradiation, where it was found that IL-6 KO mice displayed a more severe reaction, and IL-10 levels were suppressed compared to WT (Nishimura N, et al., (1999) *Immunology* 97: 77-83). This is also consistent with the IL-11 results discussed above, as LIF, IL-6 and IL-11 belong to the same family and induce the same signal cascades. Each of these cytokines is increased in lesional psoriatic skin (Bonifati C, et al., (1998)
30 *Arch. Dermatol. Res.* 290: 9-13) and is thus a potential therapeutic agent.

WE CLAIM:

1. A method for modulating inflammation in a patient, comprising the step of administering a nucleic acid encoding leukemia inhibitory factor (LIF) to a patient in an amount effective to modulate inflammation.

2. The method of Claim 1, wherein said nucleic acid is contained within a viral vector.

3. The method of Claim 2, wherein said viral vector is an adenovirus.

4. The method of claim 1, where said administering is prior to an insult which otherwise results in inflammation.

5. The method of claim 1, where said administering is approximately coincident with an insult which otherwise results in inflammation.

6. The method of claim 1 where said administering is to a site of inflammation or potential inflammation.

7. The method of claim 1 where said administering further modulates swelling.

8. The method of claim 1 where said administering further modulates macrophage infiltration into a site of inflammation or potential inflammation.

9. A method for modulating swelling associated with inflammation in a patient comprising the step of administering a nucleic acid encoding leukemia inhibitory factor (LIF) to a patient in an amount effective to modulate swelling associated with inflammation.

10. The method of Claim 9, wherein said nucleic acid is contained within a viral

vector.

11. The method of Claim 10, wherein said viral vector is an adenovirus.

5

12. The method of claim 9 where said administering is prior to an insult otherwise resulting in pain.

10

13. The method of claim 9, where said administering is approximately coincident with an insult which otherwise results in inflammation.

14. The method of claim 9 where said administering is to a site of inflammation or potential inflammation.

15

15. The method of claim 9 where said administering also modulates inflammation.

20

16. A method for modulating infiltration of macrophage associated with inflammation in a patient comprising the step of administering a nucleic acid encoding leukemia inhibitory factor (LIF) to an individual in an amount effective to modulate the infiltration of macrophage.

17. The method of Claim 16, wherein said nucleic acid is contained within a viral vector.

25

18. The method of Claim 17, wherein said viral vector is an adenovirus.

19. The method of claim 16 where said administering is prior to an insult resulting in pain.

30

20. The method of claim 16, where said administering is approximately coincident with an insult which results in inflammation.

21. The method of claim 16 where said administering is to a site of inflammation or potential inflammation.

22. The method of claim 16 where said administering also modulates inflammation.

23. The method of claim 1 or 9 or 16 wherein said modulating is reducing.

24. A method of screening for candidate agents which modulate LIF activity, said method comprising administering a candidate agent and LIF to an animal model lacking expression of LIF, wherein a change in LIF activity indicates a modulator of LIF activity, wherein said change is in relation to a control having a different concentration of the candidate agent.

25. The method of claim 24 wherein said LIF activity is characterized by at least one of the characteristics in the group consisting of a decrease in mechanical sensitivity, a decrease in thermal sensitivity, a decrease in immune cell infiltrate, an inhibition of neuronal growth factor, an inhibition of interleukin 1 beta.


ABSTRACT OF THE INVENTION

A method for inhibiting and/or reducing inflammation and/or pain in an individual is provided, as well as edema and macrophage infiltration associated with inflammation.

- 5 The method comprises administration of leukemia inhibitory factor (LIF) to a cell or an individual in an amount effective to inhibit and/or reduce inflammation and/or pain.


IPSI/CONTRA RATIOS
48TH POST CFA

FIG._1A




IPSI/CONTRA RATIOS
48TH POST CFA

FIG._1B



% INCREASE IN
FOOTPAD DIAMETER

FIG._1C






FIG._2A FIG._2B

MECHANICAL SENSITIVITY




FIG._3A

THERMAL SENSITIVITY






FIG._3B



THERMAL SENSITIVITY




FIG._5




FIGURE 6




FIGURE 7





FIGURE 8

FIGURE 9





FIGURE 10

FIGURE 11






FIGURE 12